A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis

Table 3

Distribution of total and subsets of CD8+ T cells in CFS/ME patients, MS patients, and nonfatigued controls.

CD8+ T cells (%)	CFS/ME	MS	Nonfatigued controls	value
				Overall	MS versus CFS/ME	CFS/ME versus control	MS versus control
Total; CD8+ T cells	13.25 ± 0.86	12.36 ± 1.89	13.24 ± 0.88	0.84	>0.99	>0.99	>0.99
Naïve; CD8+ T cells	33.86 ± 3.89	36.76 ± 5.76	24.20 ± 2.19	0.07	>0.99	0.12	0.29
CM; CD8+ T cells	31.88 ± 2.63	38.50 ± 2.36	32.93 ± 2.75	0.51	0.81	>0.99	0.88
EM; CD8+ T cells	12.52 ± 2.15	15.83 ± 2.77	18.64 ± 2.13	0.07	>0.99	0.08	0.51
EMRA; CD8+ T cells	10.18 ± 2.21	6.86 ± 2.22	13.38 ± 2.13	0.06	0.82	0.43	0.08